Social media

In 2025 ICON was recognised for its commitment to building an inclusive workplace. Learn more. https://ow.ly/uWXN50XSPUE

In 2025 ICON was recognised for its commitment to building an inclusive workplace. Learn more. https://ow.ly/PHN150XSPUF

At ICON, we understand that exploring a new career opportunity comes with questions. Having a clear sense of what to expect can make the experience feel more straightforward. This week, we’re sharing a five part series ...

At ICON, we understand that exploring a new career opportunity comes with questions. Having a clear sense of what to expect can make the experience feel more straightforward. This week, we’re sharing a five part series ...

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...